FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1585-1587 December 8, 1994 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Nearly two decades ago, Richard Dawkins proposed the concept that genes possess an inherent property of "selfish replication."¹ He argued, anthropomorphically, that these basic units of heredity behave in a manner that guarantees their self-perpetuation. However, a flawed gene would be eliminated from the species by selective pressure against the expression of a deleterious trait. Thus, only the most robust genes would be transmitted to subsequent generations. In this issue of the Journal, Greengard and her colleagues² describe a homozygous mutation in the gene for coagulation factor V that seems to have no adverse clinical effects. Their report suggests that . . . [Full Text of this Article]

References

Related Letters:

Factor V Leiden and Thrombophilia
Hopmeier P., Krugluger W., Simioni P., Scudeller A., Girolami A., Kalafatis M., Mann K. G., Belliveau R. R., Bauer K. A., Griffin J. H., Hajjar K. A.
Extract | Full Text  
N Engl J Med 1995; 332:1381-1384, May 18, 1995. Correspondence

This article has been cited by other articles:

• Kerlin, B. A., Yan, S. B., Isermann, B. H., Brandt, J. T., Sood, R., Basson, B. R., Joyce, D. E., Weiler, H., Dhainaut, J.-F. (2003). Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 102: 3085-3092 [Abstract] [Full Text]  
• Corral, J., Iniesta, J. A., Gonzalez-Conejero, R., Villalon, M., Vicente, V. (2001). Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood 97: 2979-2982 [Abstract] [Full Text]  
• Zivelin, A., Gitel, S., Griffin, J. H., Xu, X., Fernandez, J. A., Martinowitz, U., Cohen, Y., Halkin, H., Seligsohn, U., Inbal, A. (1999). Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C. Blood 94: 895-901 [Abstract] [Full Text]  
• Salomon, O., Steinberg, D. M., Zivelin, A., Gitel, S., Dardik, R., Rosenberg, N., Berliner, S., Inbal, A., Many, A., Lubetsky, A., Varon, D., Martinowitz, U., Seligsohn, U. (1999). Single and Combined Prothrombotic Factors in Patients With Idiopathic Venous Thromboembolism : Prevalence and Risk Assessment. Arterioscler. Thromb. Vasc. Bio. 19: 511-518 [Abstract] [Full Text]  
• Dacosta, A, Tardy-Poncet, B, Isaaz, K, Cerisier, A, Mismetti, P, Simitsidis, S, Reynaud, J, Tardy, B, Piot, M, Decousus, H, Guyotat, D (1998). Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart 80: 338-340 [Abstract] [Full Text]  
• Maher, C., Wall, C., Fanning, S. (1997). Molecular Genetics of Factor V Leiden: Genetic Origins and Modern DNA-Based Detection Strategies. SEMIN CARDIOTHORAC VASC ANESTH 1: 333-341 [Abstract]  
• Press, R. D., Liu, X.-Y., Beamer, N., Coull, B. M. (1996). Ischemic Stroke in the Elderly : Role of the Common Factor V Mutation Causing Resistance to ActivatedProtein C. Stroke 27: 44-48 [Abstract] [Full Text]  
• Hopmeier, P., Krugluger, W., Simioni, P., Scudeller, A., Girolami, A., Kalafatis, M., Mann, K. G., Belliveau, R. R., Bauer, K. A., Griffin, J. H., Hajjar, K. A. (1995). Factor V Leiden and Thrombophilia. NEJM 332: 1381-1384 [Full Text]